Velox Design Lab · Shared design

Triple-incretin triad

Research target: A GLP-1 / GIP / glucagon triple receptor agonist, optimised for synthesisability and a longer plasma half-life.
Tri-Inc α
91
✦ Likely brand-new
HAEGTFTSDYSKYLD

An incretin-style backbone tuned to be shorter and easier to make than full-length agonists.

Tri-Inc β
83
✦ Likely brand-new
YAEGTFISDYSIALD

A sister design swapping a couple of residues to probe receptor selectivity.

GlucaFuse
92
✦ Likely brand-new
HSQGTFTSDYSKYLDE

A glucagon-leaning candidate with an added acidic tail for stability.

Design your own novel peptide free →
Closest compound you can order today
Retatrutide
This brief points straight at Retatrutide — the closest characterised compound Velox stocks for this kind of research.
Designed sequences are novel hypotheses that still have to be synthesised. Retatrutide is real material you can study now — ≥99% HPLC-verified, batch Certificate of Analysis included, dispatched from the UK in 24h.
Research Retatrutide →Browse related compounds →
Velox Design Lab outputs are computational sequence predictions for in vitro research use only. They are hypotheses, not validated compounds, and are not a medicinal product, not medical advice, and not for human or veterinary use. See our Research Use Policy.